{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T13:11:58Z","timestamp":1793193118828,"version":"4.5.0"},"reference-count":99,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T00:00:00Z","timestamp":1695686400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.cell.2023.09.023","type":"journal-article","created":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T10:29:45Z","timestamp":1697452185000},"page":"4757-4772","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":208,"title":["Accelerating Alzheimer\u2019s therapeutic development: The past and future of clinical trials"],"prefix":"10.1016","volume":"186","author":[{"given":"Adam L.","family":"Boxer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reisa","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cell.2023.09.023_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2212948","article-title":"Lecanemab in Early Alzheimer's Disease","volume":"388","author":"van Dyck","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib2","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1001\/jama.2023.13239","article-title":"Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial","volume":"330","author":"Sims","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2023.09.023_bib3","article-title":"Building clinically relevant outcomes across the Alzheimer's disease spectrum","volume":"7","author":"Rentz","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib4","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1056\/NEJMp2111320","article-title":"Controversy and Progress in Alzheimer's Disease - FDA Approval of Aducanumab","volume":"385","author":"Rabinovici","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib5","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1002\/alz.13016","article-title":"2023 Alzheimer's disease facts and figures","volume":"19","author":"Association","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib6","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1126\/science.1566067","article-title":"Alzheimer's disease: the amyloid cascade hypothesis","volume":"256","author":"Hardy","year":"1992","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.09.023_bib7","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/373523a0","article-title":"Alzheimer-type neuropathology in transgenic mice overexpressing V717F beta-amyloid precursor protein","volume":"373","author":"Games","year":"1995","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.09.023_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/22124","article-title":"Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse","volume":"400","author":"Schenk","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.09.023_bib9","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1212\/01.WNL.0000148604.77591.67","article-title":"Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD","volume":"64","author":"Bayer","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.09.023_bib10","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13195-019-0529-5","article-title":"The \"rights\" of precision drug development for Alzheimer's disease","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.cell.2023.09.023_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.3001694","article-title":"If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet slowed cognitive decline?","volume":"20","author":"Haass","year":"2022","journal-title":"PLoS Biol."},{"key":"10.1016\/j.cell.2023.09.023_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/nyas.12417","article-title":"Economic analysis of opportunities to accelerate Alzheimer's disease research and development","volume":"1313","author":"Scott","year":"2014","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.cell.2023.09.023_bib13","article-title":"Who funds Alzheimer's disease drug development?","volume":"7","author":"Cummings","year":"2021","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib15","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41573-022-00391-w","article-title":"The amyloid hypothesis in Alzheimer disease: new insights from new therapeutics","volume":"21","author":"Karran","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.cell.2023.09.023_bib14","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/WCO.0000000000000912","article-title":"What is 'Alzheimer's disease'? The neuropathological heterogeneity of clinically defined Alzheimer's dementia","volume":"34","author":"Mehta","year":"2021","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib17","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1159\/000113700","article-title":"Progress in the active immunotherapeutic approach to Alzheimer's disease: clinical investigations into AN1792-associated meningoencephalitis","volume":"5","author":"Pride","year":"2008","journal-title":"Neurodegener. Dis."},{"key":"10.1016\/j.cell.2023.09.023_bib18","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1212\/01.WNL.0000159743.08996.99","article-title":"Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease","volume":"64","author":"Fox","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.09.023_bib19","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1212\/01.WNL.0000159740.16984.3C","article-title":"Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial","volume":"64","author":"Gilman","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.09.023_bib20","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa1304839","article-title":"Two phase 3 trials of bapineuzumab in mild-to-moderate Alzheimer's disease","volume":"370","author":"Salloway","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib21","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-Amyloid-beta Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cell.2023.09.023_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.jalz.2011.05.2351","article-title":"Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup","volume":"7","author":"Sperling","year":"2011","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib16","article-title":"An insider's perspective on FDA approval of aducanumab","volume":"9","author":"Wang","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamaneurol.2021.5205","article-title":"Amyloid-Related Imaging Abnormalities and beta-Amyloid-Targeting Antibodies: A Systematic Review","volume":"79","author":"Filippi","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41582-019-0281-2","article-title":"Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways","volume":"16","author":"Greenberg","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib25","doi-asserted-by":"crossref","first-page":"e1889","DOI":"10.1212\/WNL.0000000000005550","article-title":"ABBY: A\u00a0phase 2 randomized trial of crenezumab in mild to moderate Alzheimer disease","volume":"90","author":"Cummings","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.09.023_bib26","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease","volume":"370","author":"Doody","year":"2014","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib27","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13195-021-00813-8","article-title":"A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Abeta protofibril antibody","volume":"13","author":"Swanson","year":"2021","journal-title":"Alzheimer's Res. Ther."},{"key":"10.1016\/j.cell.2023.09.023_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.14283\/jpad.2022.30","article-title":"Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease","volume":"9","author":"Budd Haeberlein","year":"2022","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.cell.2023.09.023_bib29","series-title":"Surrogate Endpoint Resources for Drug and\u00a0Biologic Development","author":"Administration","year":"2018"},{"key":"10.1016\/j.cell.2023.09.023_bib30","series-title":"Congressional Inquiry into Alzheimer\u2019s Drug Faults its Maker and F.D.A","author":"Belluck","year":"2022"},{"key":"10.1016\/j.cell.2023.09.023_bib31","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nn0901-887","article-title":"The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation","volume":"4","author":"Nilsberth","year":"2001","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.cell.2023.09.023_bib32","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1212\/WNL.0000000000001877","article-title":"Amyloid-beta 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials","volume":"85","author":"Liu","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.09.023_bib33","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1056\/NEJMoa2305032","article-title":"Trial of Solanezumab in Preclinical Alzheimer's Disease","volume":"389","author":"Sperling","year":"2023","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib34","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/alz.12748","article-title":"The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease","volume":"19","author":"Rafii","year":"2023","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature22809","article-title":"Addendum: The antibody aducanumab reduces Abeta plaques in Alzheimer's disease","volume":"546","author":"Sevigny","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.09.023_bib36","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in Early Alzheimer's Disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib37","doi-asserted-by":"crossref","first-page":"414","DOI":"10.14283\/jpad.2021.56","article-title":"Donanemab (LY3002813) Phase 1b Study in Alzheimer's Disease: Rapid and Sustained Reduction of Brain Amyloid Measured by Florbetapir F18 Imaging","volume":"8","author":"Lowe","year":"2021","journal-title":"J.\u00a0Prev. Alzheimers Dis."},{"key":"10.1016\/j.cell.2023.09.023_bib38","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abc0655","article-title":"The cortical origin and initial spread of medial temporal tauopathy in Alzheimer's disease assessed with positron emission tomography","volume":"13","author":"Sanchez","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib40","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.09.023_bib41","doi-asserted-by":"crossref","first-page":"457","DOI":"10.3233\/JAD-122059","article-title":"Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807","volume":"34","author":"Chien","year":"2013","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.cell.2023.09.023_bib42","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1093\/brain\/awab248","article-title":"Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages","volume":"144","author":"Pascoal","year":"2021","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.09.023_bib43","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s43587-022-00204-0","article-title":"Biomarker modeling of Alzheimer\u2019s disease using PET-based Braak staging","volume":"2","author":"Therriault","year":"2022","journal-title":"Nat. Aging"},{"key":"10.1016\/j.cell.2023.09.023_bib44","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.cell.2023.09.023_bib45","first-page":"150","volume":"4","author":"Tariot","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib46","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","article-title":"A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease","volume":"27","author":"Salloway","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib47","series-title":"EARLY ALZHEIMER\u2019S DISEASE","article-title":"GRADUATE I AND II: EFFICACY RESULTS FROM TWO PHASE III TRIALS OF SUBCUTANEOUS GANTENERUMAB","author":"Bateman","year":"2023"},{"key":"10.1016\/j.cell.2023.09.023_bib48","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1038\/s41591-022-01942-9","article-title":"Temporal order of clinical and biomarker changes in familial frontotemporal dementia","volume":"28","author":"Staffaroni","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib49","doi-asserted-by":"crossref","first-page":"4489","DOI":"10.1093\/brain\/awac229","article-title":"Amyloid, tau and metabolic PET correlates of cognition in early and late-onset Alzheimer's disease","volume":"145","author":"Tanner","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.09.023_bib50","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1001\/jamaneurol.2023.0455","article-title":"Association of Age at Menopause and Hormone Therapy Use With Tau and beta-Amyloid Positron Emission Tomography","volume":"80","author":"Coughlan","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib51","doi-asserted-by":"crossref","first-page":"3913","DOI":"10.1016\/j.cell.2022.09.002","article-title":"X-linked ubiquitin-specific peptidase 11 increases tauopathy vulnerability in women","volume":"185","author":"Yan","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.09.023_bib52","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/brain\/awz090","article-title":"A multicentre longitudinal study of flortaucipir (18F) in normal ageing, mild cognitive impairment and Alzheimer's disease dementia","volume":"142","author":"Pontecorvo","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.09.023_bib53","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1001\/jama.2020.12134","article-title":"Discriminative Accuracy of Plasma Phospho-tau217 for Alzheimer Disease vs Other Neurodegenerative Disorders","volume":"324","author":"Palmqvist","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cell.2023.09.023_bib54","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1474-4422(21)00214-3","article-title":"Plasma phosphorylated tau 217 and phosphorylated tau 181 as biomarkers in Alzheimer's disease and frontotemporal lobar degeneration: a retrospective diagnostic performance study","volume":"20","author":"Thijssen","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib55","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jamaneurol.2022.3392","article-title":"Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial","volume":"79","author":"Pontecorvo","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib56","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","article-title":"A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease","volume":"26","author":"Barth\u00e9lemy","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib57","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1038\/s41591-023-02443-z","article-title":"CSF MTBR-tau243 is a specific biomarker of tau tangle pathology in Alzheimer's disease","volume":"29","author":"Horie","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib58","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","article-title":"Biomarkers for neurodegenerative diseases","volume":"27","author":"Hansson","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib59","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJMoa2204705","article-title":"Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS","volume":"387","author":"Miller","year":"2022","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib60","article-title":"Alzheimer's disease drug development pipeline: 2022","volume":"8","author":"Cummings","year":"2022","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib61","doi-asserted-by":"crossref","DOI":"10.1172\/JCI168553","article-title":"Tau pathology in neurodegenerative disease: disease mechanisms and therapeutic avenues","volume":"133","author":"Samudra","year":"2023","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.cell.2023.09.023_bib62","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/brain\/awz019","article-title":"Tau PET in autosomal dominant Alzheimer's disease: relationship with cognition, dementia and other biomarkers","volume":"142","author":"Gordon","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.09.023_bib63","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau5732","article-title":"Prospective longitudinal atrophy in Alzheimer's disease correlates with the intensity and topography of baseline tau-PET","volume":"12","author":"La Joie","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib64","doi-asserted-by":"crossref","DOI":"10.1126\/science.abb8255","article-title":"Tau: Enabler of diverse brain disorders and target of rapidly evolving therapeutic strategies","volume":"371","author":"Chang","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.09.023_bib65","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.neurobiolaging.2014.09.007","article-title":"Human secreted tau increases amyloid-beta production","volume":"36","author":"Bright","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.cell.2023.09.023_bib66","article-title":"Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer's disease","volume":"13","author":"Ayalon","year":"2021","journal-title":"Sci.\u00a0Transl. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/jamaneurol.2019.3812","article-title":"Reactions to Multiple Ascending Doses of the Microtubule Stabilizer TPI-287 in Patients With Alzheimer Disease, Progressive Supranuclear Palsy, and Corticobasal Syndrome: A Randomized Clinical Trial","volume":"77","author":"Tsai","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib68","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41591-021-01455-x","article-title":"Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial","volume":"27","author":"Dam","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib69","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1001\/jamaneurol.2022.1375","article-title":"Safety and Efficacy of Semorinemab in Individuals With Prodromal to Mild Alzheimer Disease: A Randomized Clinical Trial","volume":"79","author":"Teng","year":"2022","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib70","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer\u2019s disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.cell.2023.09.023_bib71","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1007\/s40265-021-01546-6","article-title":"Current Status of Clinical Trials on Tau Immunotherapies","volume":"81","author":"Ji","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.cell.2023.09.023_bib72","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/s41591-023-02326-3","article-title":"Tau-targeting antisense oligonucleotide MAPT(Rx) in mild Alzheimer's disease: a phase 1b, randomized, placebo-controlled trial","volume":"29","author":"Mummery","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib73","series-title":"First Hit on Aggregated Tau: Antisense Oligonucleotide Lowers Tangles","year":"2023"},{"key":"10.1016\/j.cell.2023.09.023_bib74","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00401-022-02444-1","article-title":"Frequency of LATE neuropathologic change across the spectrum of Alzheimer's disease neuropathology: combined data from 13 community-based or population-based autopsy cohorts","volume":"144","author":"Nelson","year":"2022","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.09.023_bib75","doi-asserted-by":"crossref","first-page":"3463","DOI":"10.1093\/brain\/awaa299","article-title":"Protein contributions to brain atrophy acceleration in Alzheimer's disease and primary age-related tauopathy","volume":"143","author":"Josephs","year":"2020","journal-title":"Brain"},{"key":"10.1016\/j.cell.2023.09.023_bib76","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1038\/s41591-023-02450-0","article-title":"Cognitive effects of Lewy body pathology in clinically unimpaired individuals","volume":"29","author":"Palmqvist","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib77","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1038\/s41591-023-02449-7","article-title":"Clinical effects of Lewy body pathology in cognitively impaired individuals","volume":"29","author":"Quadalti","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib78","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.cell.2022.12.032","article-title":"Hallmarks of neurodegenerative diseases","volume":"186","author":"Wilson","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.09.023_bib79","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1474-4422(20)30394-X","article-title":"Genetic determinants of survival in progressive supranuclear palsy: a genome-wide association study","volume":"20","author":"Jabbari","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib80","doi-asserted-by":"crossref","DOI":"10.1126\/science.add6696","article-title":"TRIM11 protects against tauopathies and is down-regulated in Alzheimer's disease","volume":"381","author":"Zhang","year":"2023","journal-title":"Science"},{"key":"10.1016\/j.cell.2023.09.023_bib81","doi-asserted-by":"crossref","first-page":"2696","DOI":"10.1016\/j.cell.2021.03.048","article-title":"Chaperone-mediated autophagy prevents collapse of the neuronal metastable proteome","volume":"184","author":"Bourdenx","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.09.023_bib82","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/j.neuron.2022.12.012","article-title":"Evolutionarily conserved regulators of tau identify targets for new therapies","volume":"111","author":"Kim","year":"2023","journal-title":"Neuron"},{"key":"10.1016\/j.cell.2023.09.023_bib83","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.tins.2021.06.007","article-title":"Cellular senescence at the crossroads of inflammation and Alzheimer's disease","volume":"44","author":"Guerrero","year":"2021","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.cell.2023.09.023_bib84","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13024-023-00608-5","article-title":"The era of cryptic exons: implications for ALS-FTD","volume":"18","author":"Mehta","year":"2023","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.cell.2023.09.023_bib85","doi-asserted-by":"crossref","DOI":"10.1016\/j.pneurobio.2022.102229","article-title":"TDP-43 pathology: From noxious assembly to therapeutic removal","volume":"211","author":"Keating","year":"2022","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.cell.2023.09.023_bib86","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/j.cell.2023.01.005","article-title":"PIKFYVE inhibition mitigates disease in models of diverse forms of ALS","volume":"186","author":"Hung","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.09.023_bib87","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1016\/j.cell.2021.07.003","article-title":"ELAVL4, splicing, and glutamatergic dysfunction precede neuron loss in MAPT mutation cerebral organoids","volume":"184","author":"Bowles","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.cell.2023.09.023_bib88","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/ng.536","article-title":"Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions","volume":"42","author":"Van Deerlin","year":"2010","journal-title":"Nat. Genet."},{"key":"10.1016\/j.cell.2023.09.023_bib89","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s00401-023-02580-2","article-title":"Limbic-predominant age-related TDP-43 proteinopathy (LATE-NC) is associated with abundant TMEM106B pathology","volume":"146","author":"Neumann","year":"2023","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.cell.2023.09.023_bib90","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1038\/s41591-019-0611-3","article-title":"Resistance to autosomal dominant Alzheimer\u2019s disease in an APOE3 Christchurch homozygote: a case report","volume":"25","author":"Arboleda-Velasquez","year":"2019","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib91","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-023-02318-3","article-title":"Resilience to autosomal dominant Alzheimer\u2019s disease in a Reelin-COLBOS heterozygous man","volume":"29","author":"Lopera","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib92","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1074\/jbc.R116.766782","article-title":"Reelin: Neurodevelopmental Architect and Homeostatic Regulator of Excitatory Synapses","volume":"292","author":"Wasser","year":"2017","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.cell.2023.09.023_bib93","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1056\/NEJMra1510062","article-title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","volume":"377","author":"Woodcock","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.cell.2023.09.023_bib94","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-055615","article-title":"Uptake of the multi-arm multi-stage (MAMS) adaptive platform approach: a trial-registry review of late-phase randomised clinical trials","volume":"12","author":"Noor","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.cell.2023.09.023_bib95","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ana.26285","article-title":"Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development","volume":"91","author":"Paganoni","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.cell.2023.09.023_bib96","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature25475","article-title":"HER kinase inhibition in patients with HER2- and HER3-mutant cancers","volume":"554","author":"Hyman","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.09.023_bib97","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41586-021-03911-7","article-title":"Structure-based classification of tauopathies","volume":"598","author":"Shi","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.cell.2023.09.023_bib98","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jalz.2016.07.005","article-title":"The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model","volume":"13","author":"Bateman","year":"2017","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.cell.2023.09.023_bib99","doi-asserted-by":"crossref","first-page":"286","DOI":"10.14283\/jpad.2021.12","article-title":"The Institute on Methods and Protocols for Advancement of Clinical Trials in ADRD (IMPACT-AD): A Novel Clinical Trials Training Program","volume":"8","author":"Berkness","year":"2021","journal-title":"J.\u00a0Prev. Alzheimers Dis."}],"container-title":["Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867423010772?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0092867423010772?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T12:10:02Z","timestamp":1758802202000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0092867423010772"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":99,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S0092867423010772"],"URL":"https:\/\/doi.org\/10.1016\/j.cell.2023.09.023","relation":{},"ISSN":["0092-8674"],"issn-type":[{"value":"0092-8674","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Accelerating Alzheimer\u2019s therapeutic development: The past and future of clinical trials","name":"articletitle","label":"Article Title"},{"value":"Cell","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cell.2023.09.023","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 University of California, San Francisco. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}